<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419831</url>
  </required_header>
  <id_info>
    <org_study_id>2000026626</org_study_id>
    <nct_id>NCT04419831</nct_id>
  </id_info>
  <brief_title>Characterizing Subjective and Physiological Responses to Stress and Pain and Cognitive Learning and Executive Function</brief_title>
  <official_title>Characterizing Subjective and Physiological Responses to Stress and Pain and Cognitive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study design is an experimental study with between groups factor (controls, chronic pain,&#xD;
      addicted individuals) and repeated measures factor of pain/stress (pain vs no pain) along&#xD;
      with a longitudinal component to assess stress, pain and addictive behaviors in daily life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposal aims to systematically examine the physiologic, neuroendocrine and behavioral&#xD;
      stress and pain responses to an adapted Cold Pressor Test and also assess specific cognitive&#xD;
      and executive function tests in community volunteers with a history of stress and trauma,&#xD;
      social users of alcohol, cannabis and individuals with alcohol use disorder, cannabis use&#xD;
      disorder, opioid use disorder, cocaine use disorder and chronic pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessments</measure>
    <time_frame>3 years</time_frame>
    <description>Pain will be assessed by asking participants, &quot;Right now, how much pain do you feel?&quot; asked using the VAS scale ranging from 0 to 100 as outlined in the Laboratory Pain Ratings assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug craving</measure>
    <time_frame>3 years</time_frame>
    <description>Drug craving will be assessed by asking participants, &quot;Right now, how much do you want to use your preferred drug?&quot; This item will be presented in all assessments throughout the study period. Participants will be asked, &quot;How much drug did you use in drinks/grams,&quot; that day in the evening prompt and in the previous day in the evening prompt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mood and anxiety assessments</measure>
    <time_frame>3 years</time_frame>
    <description>The Positive and Negative Affect Schedule (PANAS) measures positive and negative mood and anxiety measures during the initial 28-day period. Participants respond to a 20-item test using a 5-point scale ranging from very slightly or not at all (1) to extremely (5) on the EMA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Food consumption</measure>
    <time_frame>3 years</time_frame>
    <description>Food consumption will be assessed via the evening survey during the initial 28-day period. Participants will respond with the top three types of food that they ate (e.g., &quot;vegetables/salad&quot;, &quot;sweet food/dessert&quot;, &quot;white meat (e.g., fish/chicken)&quot;) and to what extent did they continue eating after feeling full (1=Not at all, 100=Very much).</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pain Response, Stress, Trauma</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Binge Heavy drinkers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabis Use Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcohol Use Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Individuals with Moderate to Severe Pain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioid Use Disorder in medication assisted treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cold Pressor Task</intervention_name>
    <description>Cold Pressor Task</description>
    <arm_group_label>Alcohol Use Disorder</arm_group_label>
    <arm_group_label>Binge Heavy drinkers</arm_group_label>
    <arm_group_label>Cannabis Use Disorder</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Individuals with Moderate to Severe Pain</arm_group_label>
    <arm_group_label>Opioid Use Disorder in medication assisted treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between ages 18-50 years;&#xD;
&#xD;
          2. Able to read and write English;&#xD;
&#xD;
          3. 50 individuals meeting DSM V criteria for Binge Heavy drinkers, using NIAAA criteria&#xD;
             for alcohol intake 50 individuals meeting DSM V criteria for Cannabis Use Disorder 50&#xD;
             individuals meeting DSM V criteria for Alcohol Use Disorder 50 Individuals with&#xD;
             Moderate to Severe Pain 50 individuals meeting DSM V criteria for Opioid Use Disorder&#xD;
             who are initiating treatment&#xD;
&#xD;
          4. Physically healthy as determined by Physical Exam, EKG and blood analyses&#xD;
&#xD;
          5. Body Mass Index (BMI) in the 18-30 range;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any psychotic disorder or current psychiatric symptoms requiring specific attention,&#xD;
             including active symptoms of psychosis or suicidal/homicidal ideation.&#xD;
&#xD;
          2. Any Current Substance Use Disorder including alcohol, cannabis, cocaine, opioids,&#xD;
             sedatives/hypnotics. For alcohol, cannabis, and opioid subjects, exclusion for the&#xD;
             abused drug will not apply.&#xD;
&#xD;
          3. Individuals taking any prescription medications or over-the counter medications&#xD;
             regularly;&#xD;
&#xD;
          4. Women with irregular menstrual cycles or who are nursing, dysmennorheic, amenorrheic,&#xD;
             menopausal, or had premenstrual dysphoric disorder or those on birth control pills;&#xD;
&#xD;
          5. Women who are pregnant as determined by the urine pregnancy test at each laboratory&#xD;
             admission;&#xD;
&#xD;
          6. Inability to give informed consent;&#xD;
&#xD;
          7. Traumatic brain injury or loss of consciousness;&#xD;
&#xD;
          8. Individuals with current or past history of seizure disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

